Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242288 | 1.00 | MCHR2 (0.48) | MCHR2ALDH1A1POLBKCNH2DRD2 | |
| SCHEMBL2758065 | 0.86 | MCHR2 (0.50) | MCHR2KCNH2DRD2SLC6A4OPRM1 | |
| SCHEMBL241428 | 0.84 | MCHR2 (0.48) | MCHR2KCNH2DRD2SLC6A4CACNA1I | |
| SCHEMBL2758063 | 0.84 | MCHR2 (0.48) | MCHR2KCNH2DRD2SLC6A4CACNA1I | |
| SCHEMBL241429 | 0.84 | MCHR2 (0.48) | MCHR2KCNH2DRD2SLC6A4CACNA1I | |
| SCHEMBL2758292 | 0.83 | SIGMAR1 (0.57) | MCHR2KCNH2DRD2SLC6A4SIGMAR1 | |
| SCHEMBL2758147 | 0.83 | SIGMAR1 (0.57) | MCHR2KCNH2DRD2SLC6A4SIGMAR1 | |
| SCHEMBL13000018 | 0.83 | SIGMAR1 (0.51) | MCHR2KCNH2DRD2SLC6A4SIGMAR1 | |
| SCHEMBL2758090 | 0.83 | MCHR2 (0.52) | MCHR2ALDH1A1KCNH2DRD2SLC6A4 | |
| SCHEMBL2758104 | 0.82 | MCHR2 (0.52) | MCHR2ALDH1A1KCNH2DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| WO-2007100664-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885ALDH1A1 2356/4885POLB 4473/4885 |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885ALDH1A1 2356/4885POLB 4473/4885 |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885ALDH1A1 2356/4885POLB 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.